PyInvesting

Market research

600671.SHG Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

SHG CNY Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts
Market cap
3B
P/E ratio
209.36
Analyst target
Not available
Dividend yield
Not available
Beta
0.01

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd is currently in a long term uptrend where the price is trading 1.9% above its 200 day moving average.

From a valuation standpoint, the stock is 55.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's total revenue sank by 31.0% to $49M since the same quarter in the previous year.

Its net income has dropped by 26.2% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 656.8% to $-16M since the same quarter in the previous year.

Based on the above factors, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd gets an overall score of 2/5.